Huan Li1, Yan Zhang2, Shu-Wei Chen1, Feng-Jiao Li3, Shi-Min Zhuang4, Li-Ping Wang1, Ji Zhang1, Ming Song1. 1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine Guangzhou, China ; Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center Guangzhou, China. 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine Guangzhou, China ; Department of Experimental Research, Sun Yat-Sen University Cancer Center Guangzhou, China. 3. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine Guangzhou, China ; Department of Operation Theater Services, Sun Yat-Sen University Cancer Center Guangzhou, China. 4. Department of Otolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou, China.
Abstract
PURPOSE: The present study aimed to investigate the clinical and prognostic significance of Flotillin1 (FLOT1) in clinically N0 tongue squamous cell cancer (cN0 TSCC). METHODS: Real-time PCR and Western blotting analyses were carried out to examine FLOT1 expression in four tongue squamous cell cancer cell lines, primary cultured normal tongue epithelial cells, and eight matched pairs of oral tongue cancer samples and adjacent non-cancerous tissue samples from the same patient. Immunohistochemistry was performed to examine FLOT1 protein expression in paraffin-embedded tissues from 181 cN0 TSCC patients. Statistical analyses evaluated the diagnostic value and the associations of FLOT1 expression with clinical parameters. RESULTS: FLOT1 mRNA and protein levels were upregulated in tongue squamous cell cancer cell lines and cancerous tissues compared with that in TEC and adjacent non-cancerous tissue samples. The level of FLOT1 protein was positively correlated with clinical stage (P = 0.001), T classification (P = 0.009), N classification (P = 0.001) and recurrence (P = 0.018). Patients with higher FLOT1 expression had shorter overall survival times. CONCLUSION: Our results suggest that overexpression of FLOT1 can be found in patients with higher pathological stage, T classification, N classification or recurrence. FLOT1 expression is associated with cN0 TSCC progression and may be valuable for the prognostic evaluation of cN0 TSCC.
PURPOSE: The present study aimed to investigate the clinical and prognostic significance of Flotillin1 (FLOT1) in clinically N0 tongue squamous cell cancer (cN0 TSCC). METHODS: Real-time PCR and Western blotting analyses were carried out to examine FLOT1 expression in four tongue squamous cell cancer cell lines, primary cultured normal tongue epithelial cells, and eight matched pairs of oral tongue cancer samples and adjacent non-cancerous tissue samples from the same patient. Immunohistochemistry was performed to examine FLOT1 protein expression in paraffin-embedded tissues from 181 cN0 TSCC patients. Statistical analyses evaluated the diagnostic value and the associations of FLOT1 expression with clinical parameters. RESULTS:FLOT1 mRNA and protein levels were upregulated in tongue squamous cell cancer cell lines and cancerous tissues compared with that in TEC and adjacent non-cancerous tissue samples. The level of FLOT1 protein was positively correlated with clinical stage (P = 0.001), T classification (P = 0.009), N classification (P = 0.001) and recurrence (P = 0.018). Patients with higher FLOT1 expression had shorter overall survival times. CONCLUSION: Our results suggest that overexpression of FLOT1 can be found in patients with higher pathological stage, T classification, N classification or recurrence. FLOT1 expression is associated with cN0 TSCC progression and may be valuable for the prognostic evaluation of cN0 TSCC.
Authors: Antti A Mäkitie; Petri Koivunen; Harri Keski-Säntti; Jyrki Törnwall; Matti Pukkila; Jussi Laranne; Marjaana Luukkaa; Jyrki Vuola; Timo Joensuu; Mikael Kajanti; Reidar Grénman Journal: Eur Arch Otorhinolaryngol Date: 2006-09-21 Impact factor: 2.503
Authors: Chuyong Lin; Zhiqiang Wu; Xi Lin; Chunping Yu; Tingting Shi; Yong Zeng; Xi Wang; Jun Li; Libing Song Journal: Clin Cancer Res Date: 2011-03-29 Impact factor: 12.531
Authors: Ai Yun Guo; Xu Jun Liang; Rui Jie Liu; Xiao Xiao Li; Wu Bi; Liu Ying Zhou; Can E Tang; Ang Yan; Zhu Chu Chen; Peng Fei Zhang Journal: Cancer Biol Ther Date: 2017-09-02 Impact factor: 4.742
Authors: Zheng Li; Yang Yang; Yang Gao; Xiaoliu Wu; Xielan Yang; Yingjie Zhu; Hongying Yang; Lin Wu; Chengang Yang; Libing Song Journal: Am J Cancer Res Date: 2015-12-15 Impact factor: 6.166